167. Marfan syndrome Clinical trials / Disease details
Clinical trials : 21 / Drugs : 40 - (DrugBank : 11) / Drug target genes : 10 - Drug target pathways : 50
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2007-005862-10-BE (EUCTR) | 29/05/2009 | 07/01/2009 | Randomized, double-blind study for the evaluation of the effect of losartan versus placebo on aortic root dilatation in patients with Marfan syndrome under treatment with beta-blockers. | Randomized, double-blind study for the evaluation of the effect of losartan versus placebo on aortic root dilatation in patients with Marfan syndrome under treatment with beta-blockers. | Marfan syndrome MedDRA version: 9.1;Level: LLT;Classification code 10026829;Term: Marfan's syndrome | Trade Name: Cozaar Product Name: Losartan INN or Proposed INN: Losartan potassium Trade Name: Coozar Product Name: Losartan INN or Proposed INN: Losartan potassium Trade Name: Coozar Product Name: Losartan INN or Proposed INN: Losartan potassium | University Hospital Ghent | NULL | Not Recruiting | Female: yes Male: yes | Belgium |